Danavorexton, a parenteral OX2R-selective agonist, potently suppressed fragmentation of sleep and cataplexy-like episodes in NT1 model mice, and robustly increased sleep latency in the Maintenance of Wakefulness Test, up to the ceiling effect of 40 min, in individuals with NT117,21. Here, HCRTR2 is linked to Cataplexy.